Altimmune, Inc. 4
4 · Altimmune, Inc. · Filed May 8, 2017
Insider Transaction Report
Form 4
Altimmune, Inc.NASDAQ:ALT
Tasker Sybil
Chief Medical Officer
Transactions
- Award
Stock Options (option to buy)
2017-05-04+48,691→ 48,691 totalExercise: $13.38Exp: 2026-04-07→ Common Stock, par value $0.0001 (48,691 underlying)
Footnotes (2)
- [F1]The option is currently exercisable to purchase 16,250 shares of the Issuer's common stock, par value $0.0001. An additional 25% of the option will vest on each of 4/8/2018, 4/8/2019, and 4/8/2020.
- [F2]Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger.